Lytix Biopharma presents third quarter 2023 results

09 Nov 2023 08:00 CET

Oslo, 09 November 2023. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo:
LYTIX), a clinical stage immuno-oncology company, today releases its third
quarter 2023 results.

Dr. Øystein Rekdal, Chief Executive Officer of Lytix Biopharma, commented: “We
continue our efforts to demonstrate the clinical benefits of LTX-315 in patients
with skin cancers. First and foremost, we are satisfied with the encouraging
disease control rate achieved in late stage and heavily pretreated melanoma
patients in the ATLAS-IT-05 study. Secondly, we recognize the large commercial
potential that could be realized through the potential use of LTX-315 in basal
cell carcinoma patients. After examining the reassuring data from the Phase II
study presented by our partner Verrica Pharmaceuticals during this quarter, we
very much look forward to the results of their entire Phase II study, which is
expected to be completed during the first half of 2024. Adding to that, we have
great expectations for the upcoming study where LTX-315 will be tested in
earlier stage melanoma patients in the neoadjuvant NeoLIPA trial at Oslo
University Hospital Radiumhospitalet during 2024.”

Highlights from the third quarter 2023, and post-period events:
* ATLAS-IT-05 – Encouraging preliminary data presented at ESMO 2023:
o Disease control rate of 43% and one patient achieving a partial response to
date
o There is evidence of tumor shrinkage in both injected and non-injected lesions

* Verrica Pharmaceuticals’ Phase II study evaluating LTX-315 for the treatment
of basal cell carcinoma (BCC):
o Complete clearance was observed in lesions treated with the highest dose
tested
o Based on the stronger than expected activity observed in patients receiving
LTX-315, Verrica has decided to accelerate the clinical development of LTX-315
and to complete the entire Phase II study in H1 2024
* Neoadjuvant study in earlier stage melanoma patients:
o An investigator led Phase II study at Oslo University Hospital,
Radiumhospitalet is being planned
o The study protocol was presented at the 15th Nordic Melanoma Meeting, October
12th


Key figures (unaudited):see attached press release

CEO Øystein Rekdal, CDO Graeme Currie and CFO Gjest Breistein will host a
webcast for investors and analysts today at 14.30 CEST. The presentation and
subsequent Q&A session will be held in English and may be viewed live by
registering here: https://forms.office.com/e/N0xJzSx0Gg

The presentation is linked to this press release (and available at
https://www.lytixbiopharma.com in the Investors’ section), and a recording of
the presentation will be made available after the presentation.

***

For more information, please contact:
Gjest Breistein, CFO
E-Mail: gjest.breistein@lytixbiopharma.com

Optimum Strategic Communications
Nick Bastin, Jonathan Edwards
E-mail: lytix@optimumcomms.com


Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient’s immune system to fight cancer. The
Company’s technology is based on pioneering research in “host defense peptides”
– nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s
lead product, LTX-315, is a first-in-class molecule representing a new and
superior therapeutic principle to kill cancer cells and boost anti-cancer
immunity, with the potential to be the ideal combination partner with other
types of immunotherapies. LTX-315 targets cancer cells and disintegrates their
cell membranes, causing immunogenic cell death and release of a patient’s tumor
specific antigens. This mode of action allows cytotoxic T cells to recognize,
infiltrate, and attack cancer cells. The Company was listed on Euronext Growth
in Oslo in June 2021, following a private placement covered by investors such as
PBM Capital, a US based, healthcare-focused investment firm.

More information:
Access the news on Oslo Bors NewsWeb site

603469_Lytix Biopharma_Q3 2023 presentation.pdf
603469_Press release Q3 2023_9 November 2023.pdf